Group items tagged

Berberine and Coptidis rhizoma as novel antineoplastic agents: a review of traditional use and biomedical investigations. Tang J, Feng Y, Tsao S, Wang N, Curtain R, Wang Y. J Ethnopharmacol. 2009 Oct 29;126(1):5-17. Epub 2009 Aug 15. PMID: 19686830 doi:10.1016/j.jep.2009.08.009 Conclusions The modern evidences of treating cancer with Huanglian and berberine have a strong linkage with traditional concept and rules of using Huanglian in CM practice. As anticancer candidates with low toxicity, berberine and its altered structure, as well as Huanglian and its formulae, will attract scientists to pursue the potential anticancer effects and the mechanisms by using technologies of genomics, proteomics and other advanced approaches. On the other hand, relatively few in vivo studies have been conducted on anticancer effects of Huanglian and berberine. The clinical application of berberine or Huanglian as novel cancer therapeutic agents requires in vivo validations and further investigations of their anticancer mechanisms.

Aspirin-triggered lipoxin A4 blocks reactive oxygen species generation in endothelial cells: a novel antioxidative mechanism. Nascimento-Silva V, Arruda MA, Barja-Fidalgo C, Fierro IM. Thromb Haemost. 2007 Jan;97(1):88-98. PMID: 17200775 DOI: 10.1160/TH06-06-0315

gentlemen: If you want to show the woman you love how much you care, take a page from a romance novel: look into her eyes, focus on what she says and really talk to her.

Novel role of the vitamin D receptor in maintaining the integrity of the intestinal mucosal barrier. Kong J, Zhang Z, Musch MW, Ning G, Sun J, Hart J, Bissonnette M, Li YC. Am J Physiol Gastrointest Liver Physiol. 2008 Jan;294(1):G208-16. Epub 2007 Oct 25. PMID: 17962355 These observations suggest that VDR plays a critical role in mucosal barrier homeostasis by preserving the integrity of junction complexes and the healing capacity of the colonic epithelium. Therefore, vitamin D deficiency may compromise the mucosal barrier, leading to increased susceptibility to mucosal damage and increased risk of IBD.

Novel omega -- 3-derived local mediators in anti-inflammation and resolution. Serhan CN. Pharmacol Ther. 2005 Jan;105(1):7-21. Review. PMID: 15626453 doi:10.1016/j.pharmthera.2004.09.002

The contributions of aspirin and microbial oxygenase to the biosynthesis of anti-inflammatory resolvins: novel oxygenase products from omega-3 polyunsaturated fatty acids. Arita M, Clish CB, Serhan CN. Biochem Biophys Res Commun. 2005 Dec 9;338(1):149-57. Epub 2005 Aug 10. Review. PMID: 16112645 doi:10.1016/j.bbrc.2005.07.181    

Novel chemical mediators in the resolution of inflammation: resolvins and protectins. Serhan CN. Anesthesiol Clin. 2006 Jun;24(2):341-64. Review. PMID: 16927933

Novel eicosanoid and docosanoid mediators: resolvins, docosatrienes, and neuroprotectins. Serhan CN. Curr Opin Clin Nutr Metab Care. 2005 Mar;8(2):115-21. Review. PMID: 15716788

Rapid appearance of resolvin precursors in inflammatory exudates: novel mechanisms in resolution. Kasuga K, Yang R, Porter TF, Agrawal N, Petasis NA, Irimia D, Toner M, Serhan CN. J Immunol. 2008 Dec 15;181(12):8677-87. PMID: 19050288

Maresins: novel macrophage mediators with potent antiinflammatory and proresolving actions. Serhan CN, Yang R, Martinod K, Kasuga K, Pillai PS, Porter TF, Oh SF, Spite M. J Exp Med. 2009 Jan 16;206(1):15-23. Epub 2008 Dec 22. PMID: 19103881 doi:10.1084/jem.20081880

Resolvins, docosatrienes, and neuroprotectins, novel omega-3-derived mediators, and their aspirin-triggered endogenous epimers: an overview of their protective roles in catabasis. Serhan CN, Gotlinger K, Hong S, Arita M. Prostaglandins Other Lipid Mediat. 2004 Apr;73(3-4):155-72. Review. PMID: 15290791

Berberine is a novel cholesterol-lowering drug working through a unique mechanism distinct from statins. Kong W, Wei J, Abidi P, Lin M, Inaba S, Li C, Wang Y, Wang Z, Si S, Pan H, Wang S, Wu J, Wang Y, Li Z, Liu J, Jiang JD. Nat Med. 2004 Dec;10(12):1344-51. Epub 2004 Nov 7. PMID: 15531889 doi:10.1038/nm1135 We identify berberine (BBR), a compound isolated from a Chinese herb, as a new cholesterol-lowering drug. Oral administration of BBR in 32 hypercholesterolemic patients for 3 months reduced serum cholesterol by 29%, triglycerides by 35% and LDL-cholesterol by 25%. Treatment of hyperlipidemic hamsters with BBR reduced serum cholesterol by 40% and LDL-cholesterol by 42%, with a 3.5-fold increase in hepatic LDLR mRNA and a 2.6-fold increase in hepatic LDLR protein. Using human hepatoma cells, we show that BBR upregulates LDLR expression independent of sterol regulatory element binding proteins, but dependent on ERK activation. BBR elevates LDLR expression through a post-transcriptional mechanism that stabilizes the mRNA. Using a heterologous system with luciferase as a reporter, we further identify the 5' proximal section of the LDLR mRNA 3' untranslated region responsible for the regulatory effect of BBR. These findings show BBR as a new hypolipidemic drug with a mechanism of action different from that of statin drugs.

Berberine--a novel approach to cholesterol lowering. Doggrell SA. Expert Opin Investig Drugs. 2005 May;14(5):683-5. PMID: 15926873

Hara hatchi bu, the Okinawan people's habit of eating only till they are 80 percent full, is thought to be one of the secrets of their extraordinary health and longevity. In addition to one of the highest percentages of people in the world who live past 100, Okinawans appear to be less prone to heart disease, diabetes and obesity. Indeed, ever since it was discovered in the 1930s that laboratory rats fed a caloric-restricted (CR) diet lived almost twice as long as their well fed counterparts, scientists have pursued caloric restriction research in the hopes of finding novel strategies for extending human life and preventing disease. Given the growing older population at risk for memory problems and the rising rates of obesity, the role of diet in maintaining peak brain performance has taken on added importance.

Ergothioneine is a naturally-occurring amino acid and is a thiourea derivative of histidine, containing a sulfur atom in the imidazole ring. This compound is made in rather few organisms, notably Actinobacteria and filamentous fungi.[1] Ergothioneine was discovered in 1909 and named after the ergot fungus from which it was first purified, with its structure being determined later, in 1911.[2] This amino acid has antioxidant properties, but its chemistry differs from conventional sulfur-containing antioxidants such as glutathione or lipoic acid. Although ergothioneine cannot be made in human cells, it is present in some tissues at high levels as it is absorbed from the diet.[3] In humans ergothioneine is taken up from the gut and concentrated in the tissues by a specific transporter called the novel organic cation transporter. However, even today, one hundred years after its discovery, precisely what ergothioneine does in the human body remains a mystery

Designed with practicing dermatologists, dermatology trainees, physicians, and scientists interested in photoprotection in mind, this concise and highly illustrated guide provides the latest knowledge of photoprotection in dermatology and cosmetic science. Clinical Guide to Sunscreens and Photoprotectionalso addresses recent important international and domestic regulatory activity and requirements on the use of novel sun protective chemicals and proper labeling of products to ensure increased consumer awareness.This concisely written, problem-oriented text explores See chapter by Bischoff-Ferrari et al. from page 119 dealing with what dose is needed for 25(OH)D level of 80 nmol/l in 97% of population

Cancer immunotherapies, including cancer vaccines, are novel investigational cancer therapies. In contrast to chemotherapy and radiotherapy regimens that are often associated with severe side effects, cancer immunotherapy stimulates the body's immune system and natural resistance to cancer, thus offering a gentler means of cancer treatment that is less damaging to the rest of the body. Surgery is generally (but not always) performed, prior to immunotherapy, to remove most of the tumor (Hanna MG, Jr. et al 2001; Jocham D et al 2004). Vaccination or immunotherapy prompts the immune system to kill residual cancer cells that persist after surgery and could result in the cancer recurring.

The vitamin D-antimicrobial peptide pathway and its role in protection against infection. Gombart AF. Future Microbiol. 2009 Nov;4:1151-65. PMID: 19895218 Vitamin D deficiency has been correlated with increased rates of infection. Since the early 19th century, both environmental (i.e., sunlight) and dietary sources (cod liver) of vitamin D have been identified as treatments for TB. The recent discovery that vitamin D induces antimicrobial peptide gene expression explains, in part, the 'antibiotic' effect of vitamin D and has greatly renewed interest in the ability of vitamin D to improve immune function. Subsequent work indicates that this regulation is biologically important for the response of the innate immune system to wounds and infection and that deficiency may lead to suboptimal responses toward bacterial and viral infections. The regulation of the cathelicidin antimicrobial peptide gene is a human/primate-specific adaptation and is not conserved in other mammals. The capacity of the vitamin D receptor to act as a high-affinity receptor for vitamin D and a low-affinity receptor for secondary bile acids and potentially other novel nutritional compounds suggests that the evolutionary selection to place the cathelicidin gene under control of the vitamin D receptor allows for its regulation under both endocrine and xenobiotic response systems. Future studies in both humans and humanized mouse models will elucidate the importance of this regulation and lead to the development of potential therapeutic applications

"The "Selfish Brain" theory describes the characteristic of the human brain to cover its own, comparably high energy requirements with the utmost of priorities when regulating energy fluxes in the organism. The brain behaves selfishly in this respect. The "Selfish brain" theory amongst other things provides a novel explanation for the origin of obesity, the severe and pathological form of overweight. The Luebeck obesity and diabetes specialist Achim Peters developed the fundamentals of this theory between 1998 and 2004. The interdisciplinary "Selfish Brain: brain glucose and metabolic syndrome" research group headed by Peters and supported by the German Research Foundation (DFG) at the University of Luebeck has in the meantime been able to reinforce the basics of the theory through experimental research. Scientists the world over now consider this work as pioneering for the study of the causes of pathological eating disorders and the development of innovative therapies."